Ringside For Zarxio At Supreme Court: Biosimilar Stakeholders Line Up
Executive Summary
High court set to determine timing of biosimilar marketing and how parties handle patent disputes in Sandoz v. Amgen. Stakeholders say the outcome will impact innovation, access to biosimilars and future litigation.
You may also be interested in...
Can Biosimilar Studies Be Conducted Solely In Healthy Volunteers?
Coherus refutes Apotex argument that Neulasta biosimilars must be studied in at least one patient population. Its application could face delay as no advisory committee meeting has been scheduled ahead of its June 9 user fee date.
Can Biosimilar Studies Be Conducted Solely In Healthy Volunteers?
Coherus refutes Apotex argument that Neulasta biosimilars must be studied in at least one patient population. Its application could face delay as no advisory committee meeting has been scheduled ahead of its June 9 user fee date.
Biosimilar Tentative Approvals Could Flow From US Supreme Court Case
If high court decides that biosimilar sponsors must wait until licensure before providing 180-day notice of commercial launch, FDA may face pressure to start granting tentative licenses for 351(k) applications, industry lawyer says.